Marinus Pharmaceuticals (MRNS)
(Real Time Quote from BATS)
$1.47 USD
+0.04 (2.80%)
Updated Jul 22, 2024 01:08 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MRNS 1.47 +0.04(2.80%)
Will MRNS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNS
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
MRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Posts New Data From Bone Disease Study
SAGE's Huntington's Disease Study Meets Primary Endpoint
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
Other News for MRNS
Class Action Lawsuit against Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
Marinus Pharmaceuticals announces China NMPA approval for ganaxolone
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action – Contact Levi & Korsinsky LLP to Learn More
Hold Rating on Marinus’s IV Ganaxolone Amid Regulatory and Commercial Uncertainty